BLRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

492.00K

-95.81%

617.00K

+141.96%

652.00K

+114.47%

Estimates Revision

The market is revising Downward the revenue expectations for BioLineRx Ltd. (BLRX) for FY2025, with the revenue forecasts being adjusted by -2.38% over the past three months. During the same period, the stock price has changed by -30.14%.

Revenue Estimates for FY2025

Revise Downward

-2.38%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-14.47%

In Past 3 Month

Stock Price

Go Down

-30.14%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

Jones Trading

Justin Walsh

Strong Buy

Hold

Downgrades

n/a

2025-04-02

Reason

Jones Trading

Justin Walsh

Price Target

n/a

2025-04-02

Downgrades

Strong Buy

Hold

Reason

JonesResearch analyst Justin Walsh downgraded BioLineRx to Hold from Buy without a price target following the Q4 report. BioLineRx is on "sounder financial footing" following cessation of U.S. commercial operations with a cash runway that extends into the second half of 2026, the analyst tells investors in a research note. However, the firm sees the stock remaining range bound until the company's pipeline assets are in-licensed or motixafortide generates additional favorable data in pancreatic cancer and gene therapy indications.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$9 → $26

2025-03-31

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$9 → $26

2025-03-31

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for BioLine RX Ltd (BLRX.O) is -1.35, compared to its 5-year average forward P/E of -1.59. For a more detailed relative valuation and DCF analysis to assess BioLine RX Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.59

Current PE

-1.35

Overvalued PE

-0.12

Undervalued PE

-3.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.16

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.12

Undervalued EV/EBITDA

-2.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

13.13

Current PS

5.02

Overvalued PS

56.27

Undervalued PS

-30.01

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BLRX News & Events

Events Timeline

No data

News

8.0

2025-11-24TipRanks

Today's Options Volatility and Implied Earnings Changes - November 24, 2025

8.0

2025-11-24TipRanks

Options Volatility and Projected Earnings Changes for the Week of November 24 – November 26, 2025

9.5

2025-11-24SeekingAlpha

BioLineRx Reports GAAP EPS of $0.00, Exceeding Expectations by $0.54; Revenue of $0.43M Falls Short by $0.24M

People Also Watch

Frequently Asked Questions

What is BioLine RX Ltd (BLRX) stock price today?

The current price of BLRX is 2.92 USD — it has decreased -2.01 % in the last trading day.

What is BioLine RX Ltd (BLRX)'s business?

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

What is the price predicton of BLRX Stock?

What is BioLine RX Ltd (BLRX)'s revenue for the last quarter?

BioLine RX Ltd revenue for the last quarter amounts to 427.00K USD, decreased -91.36 % YoY.

What is BioLine RX Ltd (BLRX)'s earnings per share (EPS) for the last quarter?

BioLine RX Ltd. EPS for the last quarter amounts to -0.00 USD, decreased % YoY.

What changes have occurred in the market's expectations for BioLine RX Ltd (BLRX)'s fundamentals?

How many employees does BioLine RX Ltd (BLRX). have?

BioLine RX Ltd (BLRX) has 28 emplpoyees as of January 10 2026.

What is BioLine RX Ltd (BLRX) market cap?

Today BLRX has the market capitalization of 12.71M USD.